Pfizer advocates experimental Alzheimer’s drug

NEW YORK — Speaking at an investor conference in New York on Tuesday, Pfizer Inc. research chief Mikael Dolsten said the company’s experimental treatment for Alzheimer''s disease is the drug industry''s "best chance" to delay progression of the illness, Reuters reported.